Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 5 (1), 17-21

New Treatments for HCV: Perspective From Asia


New Treatments for HCV: Perspective From Asia

Ming-Lung Yu et al. Clin Liver Dis (Hoboken).


Figure 1
Figure 1
DAA landscape in Asian countries. AU, Australia; DAA, directly‐acting antiviral agent; HK, Hong Kong; ID, Indonesia; JP, Japan; KR, Korea; MO, Macau; MY, Malaysia; NZ, New Zealand; P, peginterferon; PH, Philippines; R, ribavirin, SG, Singapore; TH, Thailand; TW, Taiwan; VN, Vietnam; HCV, hepatitis C virus.
Figure 2
Figure 2
HCV Practice Recommendations in the transition era of DAA in Asian countries. (2a) IFN‐eligible naïve patients without DAA available; (2b) IFN‐eligible naïve patients with DAA available; (2c) IFN‐eligible experienced patients without DAA available; (2d) IFN‐eligible experienced patients with DAA available. Abbreviations: RVR, rapid virological response, HCV RNA undetectable at week 4; EVR, early virological response, HCV RNA decline > 2 logs at week 12; cEVR, complete EVR, no RVR, but HCV RNA undetectable at week 12; HCV RNA decline > 2 logs but detectable at week 12. BL, baseline; IL28B CC, interleukin‐28B CC genotype; PegIFN, peginterferon; RBV, ribavirin; W, treatment week; G2, HCV genotype 2; DAA, directly‐acting antiviral agent.

Similar articles

See all similar articles


    1. Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age‐specific antibody to HCV seroprevalence. Hepatology 2013;57:1333‐1342. - PubMed
    1. Messina JP, Humphreys I, Flaxman A, Brown A, Cooke GS, Pybus OG, Barnes E. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology 2014. doi: 10.1002/hep.27259. Epub ahead of print. - DOI - PMC - PubMed
    1. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, Heinzen EL, et al. Genetic variation in IL28B predicts hepatitis C treatment‐induced viral clearance. Nature 2009;461:399‐401. - PubMed
    1. Huang CF, Huang JF, Yang JF, Hsieh MY, Lin ZY, Chen SC, Wang LY, et al. Interleukin‐28B genetic variants in identification of hepatitis C virus genotype 1 patients responding to 24 weeks peginterferon/ribavirin. J Hepatol 2012;56:34‐40. - PubMed
    1. Yu ML, Chuang WL. Treatment of chronic hepatitis C in Asia: when East meets West. J Gastroenterol Hepatol 2009;24:336‐345. - PubMed

LinkOut - more resources